Podcasts about r r mcl

  • 17PODCASTS
  • 43EPISODES
  • 59mAVG DURATION
  • ?INFREQUENT EPISODES
  • Oct 10, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about r r mcl

Latest podcast episodes about r r mcl

WolverHeme Happy Hour
Episode 27: Mantle Cell Masterclass with Tycel Phillips

WolverHeme Happy Hour

Play Episode Listen Later Oct 10, 2024 61:12


In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL. TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/ Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

Oncology Peer Review On-The-Go
S1 Ep115: Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Oncology Peer Review On-The-Go

Play Episode Listen Later Jun 24, 2024 8:13


At the 2024 European Hematology Association (EHA) Congress, CancerNetwork® spoke with a variety of experts in the hematologic oncology space about optimizing outcomes across different patient populations and subgroups based on updated research they presented at the meeting.  Manali Kamdar, MD, an associate professor of medicine-hematology and clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus, in Colorado, spoke about data from the phase 1 TRANSCEND NHL 001 trial (NCT02631044) supporting the use of lisocabtagene maraleucel (liso-cel; Breyanzi) in earlier lines of therapy for patients with relapsed/refractory mantle cell lymphoma (MCL).1  Specifically, Kamdar highlighted how research should continue to focus on the potential utility of liso-cel in MCL subgroups such as those with TP53 mutations or blastoid morphology. Additionally, she stated that liso-cel may need to be further tested in earlier lines of therapy for patients with diffuse large B-cell lymphoma, including those with double-hit lymphoma. Michael R. Grunwald, MD, chief of the Leukemia Division and director of the Transplantation and Cellular Therapy Program at Atrium Health's Levine Cancer Institute, in North Carolina, discussed findings from the Prospective Observational Study of Patients With Polycythemia Vera (PV) in US Clinical Practices Trial (REVEAL) exploring risk factors for disease progression in patients with polycythemia vera (PV).2 According to Grunwald, a history of thromboembolic events, elevated white blood cell counts, and higher variant allele frequencies may contribute to a patient's likelihood of experiencing progression to myelofibrosis or acute myeloid leukemia (AML). Additionally, he highlighted ongoing research into the potential molecular factors that may prognosticate disease transformation in PV among a small cohort of patients enrolled on the REVEAL trial.3 Harry P. Erba, MD, PhD, a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy and the director of the Leukemia Program and Phase I Development in Hematologic Malignancies at Duke Cancer Institute, in North Carolina, discussed the clinical implications of data from the phase 3 QuANTUM-First study (NCT02668653).4  Specifically, findings demonstrated that continuation therapy with quizartinib (Vanflyta) elicited a more pronounced survival benefit vs placebo in patients with newly diagnosed FLT3-ITD–positive AML who did not undergo allogeneic hematopoietic stem cell transplant (allo-HSCT). However, Erba noted that survival outcomes were not significantly different in the quizartinib and placebo arms among patients who received allo-HSCT. References 1.        Palomba ML, Siddiqi T, Gordon LI, et al. Subgroup analyses in patients with R/R MCL treated with lisocabtagene maraleucel by prior lines of therapy and response to Bruton tyrosine kinase inhibitor from the TRANSCEND NHL 001 MCL cohort. Presented at the European Hematology Association (EHA) 2024 Congress; Madrid, Spain; June 13-16, 2024. P1126. 2.        Grunwald M, Zwicker J, Gerds A, et al. A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV) enrolled in REVEAL. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract P1047. 3.        Crowgey E, Timmers C, Xue Z, et al. Analysis of molecular mechanisms and predictive biomarkers of disease transformation in polycythemia vera. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S217. 4.        Sekeres MA, Erba H, Montesinos P, et al. QuANTUM-First: efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S142.

Keeping Current CME
There Are Multiple Ways to Treat R/R CLL or R/R MCL: What Would the Experts Do?

Keeping Current CME

Play Episode Listen Later Jun 10, 2024 59:02


Listen to the experts discuss treatment options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and R/R mantle cell lymphoma (MCL) in 4 unique patient cases.    Credit available for this activity expires: 06/07/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000852?ecd=bdc_podcast_libsyn_mscpedu

New FDA Approvals
mRESVIA for Lower Respiratory Tract Disease, Breyanzi for R/R MCL, Sarclisa for ND MM, Onyda XR for ADHD, Bkemv for PNH and aHUS, Austedo in Huntington's

New FDA Approvals

Play Episode Listen Later Jun 3, 2024 9:29


Go here for complete show notes.   Visit learnAMAstyle.com for free downloads on medical writing and editing Nascentmc.com for medical writing assistance for your company.   mRESVIA for Lower Respiratory Tract Disease The FDA approved mRNA-1345 (mRESVIA) for preventing RSV-caused lower respiratory tract disease in adults 60 and older, based on Phase 3 trial results showing 83.7% efficacy and no serious safety concerns.  Breyanzi for R/R MCL The FDA approved lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory mantle cell lymphoma (MCL) after at least two prior therapies, demonstrating an 85.3% overall response rate in trials. Sarclisa for ND MM The FDA accepted the sBLA for isatuximab (Sarclisa) combined with VRd for treating transplant-ineligible newly diagnosed multiple myeloma, showing significant improvement in progression-free survival. Onyda XR for ADHD The FDA approved clonidine hydrochloride (Onyda XR) for treating ADHD in pediatric patients aged 6 and older, as a liquid nonstimulant medication with common side effects like somnolence and sedation. Bkemv for PNH and aHUS The FDA approved eculizumab-aeeb (Bkemv) as the first interchangeable biosimilar to eculizumab for treating PNH and atypical hemolytic uremic syndrome, requiring meningococcal vaccination prior to use. Austedo in Huntington's The FDA approved a new once-daily tablet option for deutetrabenazine (Austedo XR) for tardive dyskinesia and chorea in Huntington's disease, enhancing treatment flexibility and adherence based on long-term safety and effectiveness data.  

WolverHeme Happy Hour
LymphOMG: Pouring Over Lymphoma Abstracts from ASH

WolverHeme Happy Hour

Play Episode Listen Later Dec 29, 2023 72:38


OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion! Abstracts Discussed! SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study) Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 63:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 24, 2023 63:56


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 24, 2023 63:56


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 63:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 24, 2023 63:53


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 24, 2023 63:56


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Research To Practice | Oncology Videos
Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 31, 2023 21:28


Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics: Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00) Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36) Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14) Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16) Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23) CME information and select publications

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 74:51


Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 28, 2023 74:44


Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 28, 2023 74:44


Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 74:51


Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 28, 2023 74:51


Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

PeerView Clinical Pharmacology CME/CNE/CPE Video
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 28, 2023 74:44


Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

Research To Practice | Oncology Videos
Lymphomas | Oncology Today with Dr Neil Love: Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 2, 2023 88:04


Featuring perspectives from Dr Matthew Lunning, including the following topics: •      Potential role of polatuzumab vedotin/R-CHP in therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) (00:00) •      Association between metabolic tumor volume and clinical outcomes with loncastuximab tesirine in the LOTIS-2 trial and axicabtagene ciloleucel in the ZUMA-7 trial (10:54) •      Chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas: Activity, tolerability and patient selection (22:16) •      Efficacy of and durable complete responses with bispecific antibodies in patients with DLBCL (36:48) •      Five-year results and overall survival update from the Phase III AUGMENT study evaluating rituximab and lenalidomide (R2) versus rituximab and placebo for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (42:44) •      Activity and safety of tazemetostat in combination with (R2) in patients with R/R follicular lymphoma (FL) (44:52) •      Long-term clinical outcomes with CAR T-cell therapies for patients with R/R FL (46:50) •      Available data with and ongoing studies of bispecific antibodies for R/R FL (50:23) •      Design and outcomes of the SHINE and TRIANGLE studies in mantle cell lymphoma (MCL); evolving role of transplantation for MCL (1:00:38) •      Real-time monitoring of minimal residual disease in patients receiving acalabrutinib with (R2) for treatment-naïve MCL (1:13:29) •      Assessment of durable responses after brexucabtagene autoleucel for R/R MCL in the ZUMA-2 trial (1:15:29) •      High complete response rates with glofitamab for patients with heavily pretreated MCL (1:19:00) •      Nivolumab with ICE (ifosfamide/carboplatin/etoposide) as first salvage therapy for patients with high-risk R/R Hodgkin lymphoma (1:21:04) •      Efficacy and safety of camidanlumab tesirine in patients with R/R classical Hodgkin lymphoma (1:23:07) •      Importance of brain-to-vein time in patients receiving CAR T-cell therapy (1:25:37) CME information and select publications

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2023 48:35


Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 1, 2023 48:43


Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

PeerView Internal Medicine CME/CNE/CPE Video Podcast
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 1, 2023 48:43


Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2023 48:35


Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 1, 2023 48:35


Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

PeerView Clinical Pharmacology CME/CNE/CPE Video
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Mar 1, 2023 48:43


Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don't miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2022 59:58


Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 4, 2022 59:49


Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 4, 2022 59:49


Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2022 59:58


Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2022 59:58


Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Oct 4, 2022 59:49


Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 9, 2022 69:29


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 9, 2022 69:38


Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

PCE
ASCO 2022: What's New in Mantle Cell Lymphoma

PCE

Play Episode Listen Later Jun 30, 2022 24:26


In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCLUpdated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCLResults from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLLPreliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapiesPresenters:Tycel J. Phillips, MD Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow TransplantationAssociate Professor of MedicineUniversity of Michigan Rogel Cancer Center Ann Arbor, MichiganAmy Goodrich, RN, MSN, CRNP-ACResearch Associate, Department of MedicineJohns Hopkins UniversityNurse Practitioner, Department of MedicineThe Sidney Kimmel Comprehensive Cancer CenterBaltimore, MarylandContent supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Link to full program, including a downloadable highlights slideset:https://bit.ly/3yufCU4

ACCRU Transformative Research
Dr. Catherine Diefenbach on the Promise of New Therapies for Mantle Cell Lymphoma

ACCRU Transformative Research

Play Episode Listen Later Apr 1, 2022 14:25


In this episode, podcast host Dr. Ciara O'Sullivan interviews Dr. Catherine Diefenbach about her innovative research for relapsed mantle cell lymphoma. Dr. Diefenbach is currently director of hematology translational research as well as director of the Clinical Lymphoma Program at NYU's Langone Perlmutter Cancer Center. Dr. Diefenbach discusses a current ACCRU study that has the potential to prolong the survival of R/R MCL patients, including BTK inhibitor-resistant patients, or even have a role in the frontline treatment of elderly or unfit patients who are ineligible for aggressive chemo-immunotherapy.